Trials / Completed
CompletedNCT02828397
Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects
A Randomized, Open-Label, Parallel Group Study of the Pharmacokinetics, Safety, and Tolerability of a Single Intramuscular (IM) Injection of REGN2222 Produced by 2 Different Cell Lines in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Primary Objective: Determine blood concentrations of two formulations of REGN2222 Secondary Objective: Assess safety and tolerability of REGN2222
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN2222 |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2016-07-11
- Last updated
- 2016-11-04
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02828397. Inclusion in this directory is not an endorsement.